Jason Westin, MD

Articles by Jason Westin, MD

Front-Line Treatment of DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

ByJason Westin, MD

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Jason Westin, MD

Articles by Jason Westin, MD

Front-Line Treatment of DLBCL

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies